Compositions comprising propionibacterium acnes bacteriophages for treating acne

a technology of acne and bacteriophages, which is applied in the direction of viruses/bacteriophages, drug compositions, peptides/protein ingredients, etc., can solve the problems of not being able to develop a novel acne drug in over 30 years, current treatments including benzoyl peroxide and antibiotics are quite ineffective, and the most effective treatment—isotretinoin—is limited to a small set of patients

Pending Publication Date: 2021-11-04
PHI THERAPEUTICS INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite a clear need for innovation, there has not been a novel acne drug in over 30 years.
Current treatments including benzoyl peroxide and antibiotics are quite ineffective, and the most effective treatment—isotretinoin—is limited to a small set of patients due to dangerous side effects (including birth defects, liver damage, and suicide).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions comprising propionibacterium acnes bacteriophages for treating acne
  • Compositions comprising propionibacterium acnes bacteriophages for treating acne
  • Compositions comprising propionibacterium acnes bacteriophages for treating acne

Examples

Experimental program
Comparison scheme
Effect test

embodiments

[0184]Embodiments and examples are provided below to facilitate a more complete understanding of the invention. The following embodiments and examples illustrate the exemplary modes of making and practicing the invention. However, the scope of the invention is not limited to specific embodiments disclosed in these embodiments and examples, which are for purposes of illustration only, since alternative methods can be utilized to obtain similar results.

[0185]Embodiments include Embodiments P1 to P56 following:

[0186]Embodiment P1. A composition consisting essentially of at least one Propionibacterium acnes bacteriophage, at least one anti-acne compound, and a pharmaceutically acceptable carrier.

[0187]Embodiment P2. A composition comprising at least one Propionibacterium acnes bacteriophage, at least one anti-acne compound, and a pharmaceutically acceptable carrier, wherein the composition does not comprise a probiotic bacterium.

[0188]Embodiment P3. The composition of Embodiment P2, whe...

example 2

Bacteria

Genotypic Characterization of Probiotic Strains.

[0305]Strains of P. acnes were characterized based on point mutations in the 16S rDNA sequence which leads to phylogenetic sorting into pathogenic and probiotic strain types, and the absence of a linear plasmid found in pathogenic strains, which carries virulence factors. Using 16S-specific primers the full 16S rDNA sequence of each P. acnes strain was amplified and Sanger-sequenced. A probiotic strain was identified as having ribosequence (RS) of ProI or ProII. ProI strains have T838C and C1322T mutations relative to the KPA171202 type strain's 16S rDNA sequence (NIH Accession No. NC_006085.1). ProII strains have C986T and T992C mutations relative to the KPA171202 sequence. Further, using specific primer pairs, the presence or absence of a linear plasmid within each strain was determined. Probiotic strains were identified as lacking this plasmid, which carries an extrachromosomal lipase as well as the Tad (tight adhesion) viru...

example 3

hage Stability in Compositions with Anti-Acne Compounds

[0314]In order to determine whether the phage was stable in co-formulation with either salicylic acid or benzoyl peroxide (BPO), the phage was co-incubated with these agents at a low and high concentration. The range of concentrations was determined by the permitted concentrations of these agents specified in the United States Food and Drug Administration (FDA) acne monograph for over-the-counter use. For salicylic acid, this is 0.5% to 2% (w / v), while for BPO the range is 2.5% to 10% (w / v). Buffered solutions of phage were added to these agents, and its stability at 4° C. was tested over 60-90 days. FIG. 15 shows that the phages are stable in the presence of both low and high doses of salicylic acid. In contrast, FIG. 16 shows that benzoyl peroxide destabilizes the phages, and the observed rate of decrease in phage viability is steeper at a higher concentration of BPO.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
weight/volumeaaaaaaaaaa
compositionaaaaaaaaaa
Login to view more

Abstract

Provided herein are, inter alia, compositions, systems, and methods for preventing or treating acne. Included are compositions, combinations, systems, and methods comprising at least one Propionibacterium acnes bacteriophage, at least one anti-acne compound, and a pharmaceutically acceptable carrier. Also included are compositions, combinations, and systems comprising a Propionibacterium acnes bacteriophage and an enzyme. Methods for preventing or treating acne are also provided.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application cairns the benefit of priority to U.S. Provisional Application No. 62 / 488,326, filed Apr. 21, 2017, which is hereby incorporated by reference in its entirety and or all purposes.GOVERNMENT SUPPORT[0002]This invention was made with government support under Grant No. 1R43AR068172-01 awarded by the National Institutes of Health. The government has certain rights in the invention.INCORPORATION-BY-REFERENCE OF SEQUENCE LISTING[0003]The content of the text file named “052004-503001WO_SequenceListing.TXT”, which was created on Apr. 20, 2018, and is 101,782 bytes in size, is hereby incorporated by reference in its entirety.BACKGROUND[0004]Acne is a nearly universal condition that affects more than 80% of all people worldwide. This chronic skin condition is complex but the main etiological agent is Propionibacterium acnes whose overgrowth leads to inflammation that causes pimples. Despite a clear need for innovation, there has not...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K8/99A61Q19/00A61K8/66A61K8/368A61K8/23A61K8/34A61K8/22A61K8/06A61K8/67A61P17/10
CPCA61K8/99C12Y304/21064A61K8/66A61K8/368A61K8/23A61K8/347A61K8/22A61K8/062A61K8/064A61K8/671A61P17/10C12Y105/01001C12Y111/01C12Y304/21062A61Q19/00A61K35/76C12N7/00C12N2795/10321C12N2795/10332A61K45/06A61K31/327A61K31/60A61K33/04A61K2300/00A61K31/05A61K38/47A61K38/48A61K38/446A61K9/107A61K9/0014
Inventor VARMA, YUGVAN PROOYEN, NANCY
Owner PHI THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap